Series B Healthcare Companies: The Commercial Playbook Investors Expect

Series B Due Diligence: What Investors Really Want

Series B due diligence looks different than Series A. Investors already believe the product works. What they are testing now is whether the commercial engine behind it can repeat itself without the founder closing every deal personally. After 25 years building and evaluating healthcare revenue organizations, here is what investors are actually looking for before they sign the term sheet, and what it takes to have it in place.

The Question Changes from Does It Work to Does It Repeat

At seed and Series A, investors bet on the founder's ability to close deals personally. By Series B, that same founder-led pattern becomes a red flag. If the CEO is still the primary closer on every enterprise deal, investors read that as a business that cannot scale past one person's calendar.

What they want to see instead is a sales process that produces similar outcomes regardless of who runs it. Defined stages, consistent qualification criteria, and a team that can execute the process without the founder in the room are essential.

Pipeline Math That Survives Scrutiny

Every founder walks into a Series B pitch with a pipeline slide. Few pipelines survive real diligence. Investors will ask for win rates by stage, average deal size, sales cycle length, and how those numbers have trended over the last four to six quarters.

If you cannot produce that history cleanly, the pipeline slide becomes a liability instead of an asset. Build the reporting discipline before the round, not during it.

Pricing Discipline Before Scale, Not After

Healthcare pricing tends to drift. Early deals get discounted to close logos, and enterprise contracts get customized ad hoc. By Series B, nobody can fully explain why two similar customers pay different prices.

Investors read pricing inconsistency as margin risk. A defensible pricing model, one a sales team can execute without escalating every deal to the CEO, is one of the clearest signals of commercial maturity a healthcare company can show.

A Commercial Leader Who Owns the Number

Somewhere around Series B, the question of who owns revenue stops being rhetorical. Investors want a named person, not a committee, accountable for the number. This could be a full-time CRO or a fractional executive who is embedded and accountable to the board.

What matters less than the title is whether that person can walk the board through the pipeline, the pricing model, and the hiring plan without the founder translating for them.

What Health System and Enterprise Buyers Add to the Story

Series B healthcare companies selling into health systems face a diligence question their software-only peers do not: how long does your sales cycle actually take? What happens to revenue timing if a single enterprise deal slips a quarter?

Investors who have seen this pattern before will ask to see the committee structure, the procurement timeline, and a pipeline coverage ratio that accounts for these longer cycles. A team that has already mapped this out looks materially more credible than one improvising the answer live.

Preparing for Your Next Round

None of this is about being perfect. It is about being able to answer the questions before they are asked. A repeatable sales process, clean pipeline reporting, disciplined pricing, and a named commercial owner are the four things that separate a Series B round that closes smoothly from one that drags into extended diligence.

If you are heading into a raise and cannot yet answer these questions cleanly, that is fixable in the ninety days before the process starts. It is exactly the work we do at Harborline.

The Importance of Execution

Execution is everything. Investors want to see that you can deliver results. They want to know that your team can operate independently and drive revenue growth. This is not just about having a good product; it’s about having a solid commercial strategy that works.

A well-defined sales process is crucial. It should be repeatable and scalable. Your team must understand their roles and responsibilities. They should be able to close deals without relying on the founder. This is what investors are looking for.

Building a Sustainable Revenue Model

A sustainable revenue model is vital for growth. You need to demonstrate that your pricing strategy is sound. Investors will scrutinize your pricing structure. They want to see consistency across your customer base.

If your pricing varies significantly, it raises red flags. It signals a lack of control over your revenue. A well-structured pricing model shows that you understand your market and can execute effectively.

The Role of Data in Decision Making

Data is your ally. Use it to back up your claims. Investors want to see metrics that demonstrate your growth potential. This includes your sales cycle, win rates, and customer acquisition costs.

Having this data at your fingertips will give you an edge. It shows that you are prepared and understand your business inside and out.

Conclusion: Ready for Series B?

As you prepare for your Series B raise, focus on these key areas. Ensure you have a repeatable sales process, clean pipeline reporting, disciplined pricing, and a named commercial leader.

These elements will set you apart. They will demonstrate to investors that you are ready for the next level. If you need help getting there, reach out. We can guide you through the process.

About the Author

Sarah Kerns is the founder of Harborline Growth Advisory and a healthcare commercial executive with more than 25 years of experience building and scaling revenue organizations. She advises PE-backed and founder-led healthcare companies on growth strategy, go-to-market execution, pricing, enterprise sales, and commercial leadership.

If you are heading into a Series B raise, this is exactly the diagnostic conversation we start with. We are happy to have it with you.

---

Related reading: What PE Investors Actually Want From Your Commercial Team